Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity RatioInvested CapitalReturn on AssetsReturn on Capital Employed

Cardiol Therapeutics (CRDL) Enterprise Value (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Enterprise Value readings, the most recent being -$43.8 million for Q4 2022.

  • On a quarterly basis, Enterprise Value rose 34.18% to -$43.8 million in Q4 2022 year-over-year; TTM through Dec 2022 was -$43.8 million, a 34.18% increase, with the full-year FY2022 number at -$43.8 million, up 34.18% from a year prior.
  • Enterprise Value hit -$43.8 million in Q4 2022 for Cardiol Therapeutics, up from -$64.3 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$10.8 million in Q4 2020 to a low of -$66.6 million in Q4 2021.
  • Median Enterprise Value over the past 3 years was -$43.8 million (2022), compared with a mean of -$39.0 million.
  • Biggest five-year swings in Enterprise Value: tumbled 518.7% in 2021 and later skyrocketed 34.18% in 2022.
  • Cardiol Therapeutics' Enterprise Value stood at -$10.8 million in 2020, then tumbled by 518.7% to -$66.6 million in 2021, then skyrocketed by 34.18% to -$43.8 million in 2022.
  • The last three reported values for Enterprise Value were -$43.8 million (Q4 2022), -$64.3 million (Q3 2022), and -$65.8 million (Q2 2022) per Business Quant data.